Faulding's startup injectable and device businesses, acquired in early 1996, continued to develop their respective injectable drug and medical device product lines, including the commercial launch of acyclovir injection, the generic version of Zovirax(R) brand of acyclovir sodium sterile powder, following expiration of the brand product's patent on April 23, 1997, and the shipment of the first commercial quantities of the company's Safe-Connect(TM) Valve, a needle-less intravenous connector that is intended to reduce the incidence of needle-stick injuries in conjunction with the administration of intravenous medications.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.